Prescott Group Urges PharmAthene Shareholders to Vote Against Proposed Theraclone Merger

Prescott Group Capital Management, a greater than 10% shareholder of PharmAthene, Inc. (NYSE MKT:

), who has previously urged shareholders to vote against the Theraclone merger based largely on the lack of proper disclosures, now questions the quality of due diligence performed by PharmAthene's Board of Directors after Theraclone announced on November 27, 2013 that: “Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, today announced that it has received notification from the Biomedical Advanced Research and Development Authority (BARDA) informing the Company that their proposal, “Broad spectrum anti influenza A M2e fully human monoclonal antibody TCN 032: Determination of efficacy in serious influenza disease,” was not selected